Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03404648 · ClinicalTrials.gov registry record · Phase 3

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

A Phase 3 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 3
Development phase
19
Enrollment target

NCT03404648: Completed Phase 3 study, sponsored by Mayo Clinic.

NCT03404648 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03404648, a Phase 3 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 3
Development phase
19 participants
Enrollment target

Study Summary

The purpose of this study is to find out if a PET/MR scan in combination with standard MRI and CT scans can improve the early detection and treatment of patients with prostate cancer.

Primary Outcome

Measured by maximum standardized uptake value (SUVmax) of indexed lesions. SUV is calculated as ratio of concentration of tissue reactivity divided by dose at time of injection divided by body weight.

Interventions

  • DRUG Gadobutrol
  • DRUG C-11 choline PET tracer
  • DEVICE PET/MR scanner

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2017-11-01
Est. Completion 2020-01-23
Phase Phase 3
Mayo Clinic

2,844 total trials

What the finished NCT03404648 record still lists

NCT03404648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 3 interventions - of which Gadobutrol is the first listed.

NCT03404648 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03404648 about?

NCT03404648 is a clinical study titled "Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI". The purpose of this study is to find out if a PET/MR scan in combination with standard MRI and CT scans can improve the early detection and treatment of patients with prostate cancer.

What is the current status of trial NCT03404648?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2017-11-01. Estimated completion is 2020-01-23.

What interventions are being tested in trial NCT03404648?

The interventions under investigation include: Gadobutrol (DRUG), C-11 choline PET tracer (DRUG), PET/MR scanner (DEVICE).

Who is sponsoring clinical trial NCT03404648?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03404648's enrollment target sits among peer trials

19 1969th of 2000 higher than 31 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03404648, the US trial registry maintained by the National Library of Medicine. NCT03404648 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.